secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2021-09-23T23:59:59+00:00
Accession:  0001213900-21-049470
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium appoints Swaminathan as Chief Business Officer, Desai as CMO; Berger resigns
--------------------------------------------------------------------------------

- Mark Berger resigns as CMO effective Sept 24, 2021; no disagreement with company.
- Arun Swaminathan, Ph.D., appointed Chief Business and Commercial Officer; previously at Alteogen, BMS.
- Avinash Desai, M.D., promoted to CMO from EVP Clinical Development; will lead BLA filing for Iomab-B.
- Paul Diamond, Ph.D., appointed VP Patent and Legal Counsel; 20+ years IP experience.
- Phase 3 SIERRA trial enrollment complete; commercial planning for Iomab-B begins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/0001213900-21-049470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/ea147815-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-049470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer